Full-Time
Rust Software Engineering Lead
RELX
1,001-5,000 employees
Provides analytics and decision tools for professionals
No salary listed
Senior, Expert
Sydney NSW, Australia
- Technical competence is critical
- Passion for communication and collaboration across the business.
- Solid experience creating and maintaining web based and API-based applications ideally in Rust.
- Demonstrate having built non-trivial Rust projects, ideally web-related
- Comfortable with Javascript/Typescript
- Ability to communicate clearly, both in written and verbal, and collaborate effectively with a remote team
- Strong documentation skills and the mindset of an untested code is a broken code
- Autonomous, dependable, responsible, and committed.
- Building front-end Web Assembly applications with a strong preference on Leptos
- Machine learning problem solving experience
- Developed for/with AWS Serverless technologies (API Gateway, Lambda, DynamoDB...).
- Deep understanding of data structures and time complexity analysis of algorithms.
- Extensive experience building high-scale, concurrent systems and measuring throughout.
- You will work in close collaboration with our SVP of Architecture, our engineering team and our product team to:
- Write and re-write hardened, documented, and tested web and API-based applications
- Build our growing collection of libraries
- Define and enforce best practices of an expanding Rust team
- Green-field work; front-end applications are written in Rust, using Leptos for WASM and Tailwind for CSS.
- Preference on event-based architectures, cloud (AWS) and serverless.
RELX provides information-based analytics and decision tools tailored for professionals and businesses across various sectors. The company operates in four key areas: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. Its products utilize extensive data and analytics to assist clients, such as researchers, healthcare professionals, legal practitioners, and business executives, in making informed decisions and enhancing productivity. RELX stands out from competitors with its subscription-based business model, which ensures a consistent revenue stream, alongside income from transactional sales and advertising. The company's goal is to support corporate responsibility initiatives, focusing on diversity, social justice, and sustainable development, while actively contributing to the United Nations' Sustainable Development Goals (SDGs) through its offerings.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
1894
Simplify's Take
What believers are saying
- Elsevier's AI framework sets a new standard for responsible AI in healthcare.
- Embase's expansion enhances evidence-based decision-making in pharmaceuticals and medical devices.
- ScienceDirect AI significantly reduces research time, supporting better research outcomes.
What critics are saying
- AI integration in clinical tools may face scrutiny over potential clinical harm.
- Data management challenges in Embase could slow research and regulatory processes.
- ScienceDirect AI may encounter issues with research reproducibility and data accuracy.
What makes RELX unique
- RELX excels in diverse industries with specialized analytics and decision tools.
- The company's subscription model ensures a steady stream of recurring revenue.
- RELX's commitment to corporate responsibility aligns with global sustainable development goals.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Mental Health Support
Family Planning Benefits
Health Savings Account/Flexible Spending Account
Flexible Work Hours
Remote Work Options
Company News
Clinician-centered framework will be featured in upcoming issue of the Open AccessJournal of the American Medical Informatics Association (JAMIA)Initial evaluations of ClinicalKey AI show high accuracy and usefulness in responses amongst cliniciansNEW YORK, June 4, 2025 /PRNewswire/ -- Elsevier, a global leader in medical information and data analytics, unveiled a groundbreaking evaluation framework for assessing the performance and safety of generative AI-powered clinical reference tools. This innovative approach has been developed for all Elsevier Health generative AI solutions, including ClinicalKey AI, Elsevier's advanced clinical decision support platform, and sets a new standard for responsible AI integration in healthcare. It will be featured in a future issue of the Open Access Journal of the American Medical Informatics Association (JAMIA).The framework, designed with input from clinical subject matter experts across multiple specialties, evaluates AI-generated responses along five critical dimensions: query comprehension, response helpfulness, correctness, completeness, and potential for clinical harm. It serves as a comprehensive assessment to ensure that AI-powered tools not only provide accurate and relevant information but also align with the practical and current needs of healthcare professionals at the point of care.Omry Bigger, President of Clinical Solutions at Elsevier: "This evaluation framework not only supports innovation and advancements to improve patient care but adds an extra layer of review and assessment to ensure physicians are armed with the most accurate information possible. It's a critical step in the implementation of responsible AI for healthcare providers and patients."In a recent evaluation study of ClinicalKey AI, Elsevier worked with a panel of 41-board certified physicians and clinical pharmacists to rigorously test responses generated by the tool for a diverse set of clinical queries. That panel evaluated 426 query-response pairs, and results demonstrated impressive performance, with 94.4% of responses rated as helpful, 95.5% assessed as completely correct, with just 0.47% flagged for potential improvements.Leah Livingston, Director of Generative AI Evaluation for Health Markets at Elsevier, said: "These results reflect not just strong performance, but the real value of bringing clinicians into the evaluation process
London, 6 May 2025 – Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device. Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and RD organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence
Data from studies conducted in more than 200 countries supports greater access to research and facilitates systematic reviews, clinical trial design, medical device approvals and improved drug safetyLONDON, May 6, 2025 /PRNewswire/ -- Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device.Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and R&D organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence. This process becomes challenging when data must be sourced from differing platforms, and regulatory and compliance requirements continue to evolve.The addition of ClinicalTrials.gov data to Embase will improve researcher workflows by making clinical data searchable within Embase's user-friendly interface
Trade attendees gathered in anticipation for the opening day of IASEA 2025. SINGAPORE, Apr 21, 2025 - (ACN Newswire) - The 8th edition of inter airport Southeast Asia (IASEA) was held in Singapore from 25-27 March 2025. Spanning across 6,259 sqm of exhibition space, the airport exhibition and conference brought together 3,621 industry trade professionals from 53 countries and regions, and featured 134 exhibiting companies including pavilions representing Germany, Italy, Japan and Singapore. The event saw a 43% increase in exhibitor size and a 15.6% rise in attendee numbers, underscoring the rising significance of IASEA as a platform for productive discussions. The event's achievement is also attributed to the increasing demands of operators and the rapid development and expansion of airports in Asia
Veteran Fraud Prevention Leader Joins LexisNexis Risk Solutions to Strengthen Program Integrity and Protect Public FundsWASHINGTON, April 1, 2025 /PRNewswire/ -- LexisNexis® Risk Solutions today announced the addition of Glenn Prager as Executive Director of Government Risk Solutions, reinforcing its commitment to safeguarding the integrity of our nation's critical social safety nets. Prager, a proven leader in combating fraud, waste, and abuse, brings over two decades of public and private sector experience leveraging data, analytics, and technology to ensure benefits reach those who truly need them. Glenn will work across key markets, including the U.S. Department of Health and Human Services, State and Local Medicaid Departments, and Inspector General Offices."With today's rapidly evolving fraud landscape, ensuring the integrity of federal and state benefit programs is more critical than ever," said Haywood Talcove, CEO of LexisNexis Risk Solutions – Government. "Glenn Prager's unparalleled expertise in program integrity, forensic auditing, and multi-jurisdictional fraud investigations makes him an invaluable addition to our team. His leadership will strengthen our ability to support government agencies in their mission to protect public funds, while ensuring those in need receive essential services."Prager's career has been defined by his dedication to strengthening government oversight, developing anti-fraud strategies, and enhancing compliance across Medicare, Medicaid, and other federally funded programs